ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)
China · Delayed Price · Currency is CNY 35.35
+0.45 (1.29%)
Sep 9, 2026, 4:00 PM EDT
ChengDa Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 478.62 | 404.79 | 330.85 | 413.28 | 411.34 | 415.59 |
Other Revenue | 0.79 | 1.58 | 2.28 | 1.03 | 0.12 | 0.14 |
| 479.41 | 406.37 | 333.13 | 414.3 | 411.46 | 415.73 | |
Revenue Growth | 36.36% | 21.99% | -19.59% | 0.69% | -1.03% | 11.44% |
Cost of Revenue | 342.74 | 269.25 | 207.33 | 238.93 | 228.55 | 215.7 |
Gross Profit | 136.67 | 137.12 | 125.8 | 175.37 | 182.92 | 200.02 |
Selling, General & Admin | 107.63 | 111.59 | 99.58 | 85.59 | 88.01 | 66.83 |
Research & Development | 42.77 | 40.18 | 93.71 | 27.46 | 19.44 | 17.22 |
Other Operating Expenses | 3.71 | 3.86 | 3.22 | 3.57 | 4.15 | 2.47 |
Operating Expenses | 153.67 | 156.26 | 194.8 | 117.69 | 112.65 | 87.95 |
Operating Income | -16.99 | -19.13 | -69 | 57.68 | 70.27 | 112.08 |
Interest Expense | -1.07 | -2.28 | -0.3 | - | -0.2 | -1.4 |
Interest & Investment Income | 6.7 | 13.86 | 32.81 | 48.19 | 40.25 | 0.26 |
Currency Exchange Gain (Loss) | -0.87 | -0.12 | 2.4 | 1.45 | 4.7 | -1.51 |
Other Non Operating Income (Expenses) | -5.46 | -0.04 | 2.91 | -5.06 | -0.16 | -0.1 |
EBT Excluding Unusual Items | -17.7 | -7.72 | -31.18 | 102.26 | 114.87 | 109.33 |
Gain (Loss) on Sale of Investments | 5.06 | 2.85 | 1.6 | - | 0.39 | - |
Gain (Loss) on Sale of Assets | -0.13 | 0.04 | 0.2 | 0 | -0.53 | -0.02 |
Asset Writedown | -15.66 | -14.99 | -2.53 | -3.51 | -3.43 | -2.62 |
Other Unusual Items | 4.36 | 6.56 | 4.72 | 5.5 | 8.81 | 8.6 |
Pretax Income | -24.06 | -13.26 | -27.18 | 104.25 | 120.11 | 115.29 |
Income Tax Expense | -1.4 | -1.3 | 0.46 | 13.15 | 13.63 | 15.01 |
Earnings From Continuing Operations | -22.66 | -11.96 | -27.64 | 91.1 | 106.48 | 100.27 |
Minority Interest in Earnings | 0.21 | 0.04 | -0.46 | -0.12 | 0.01 | 0.16 |
Net Income | -22.45 | -11.93 | -28.1 | 90.98 | 106.48 | 100.44 |
Net Income to Common | -22.45 | -11.93 | -28.1 | 90.98 | 106.48 | 100.44 |
Net Income Growth | - | - | - | -14.56% | 6.02% | -17.11% |
Shares Outstanding (Basic) | 151 | 152 | 152 | 155 | 151 | 116 |
Shares Outstanding (Diluted) | 151 | 152 | 152 | 155 | 151 | 116 |
Shares Change | 0.04% | -0.30% | -1.75% | 2.12% | 30.56% | -0.00% |
EPS (Basic) | -0.15 | -0.08 | -0.18 | 0.59 | 0.70 | 0.87 |
EPS (Diluted) | -0.15 | -0.08 | -0.18 | 0.59 | 0.70 | 0.87 |
EPS Growth | - | - | - | -16.33% | -18.80% | -17.11% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 7.16 | -35 | -257.72 | -32.6 | -158.03 | -55.56 |
Free Cash Flow Per Share | 0.05 | -0.23 | -1.70 | -0.21 | -1.04 | -0.48 |
Dividend Per Share | 0.200 | 0.200 | 0.200 | 0.200 | 0.188 | 0.281 |
Dividend Growth | 0% | 0% | 0% | 6.67% | -33.34% | - |
Gross Margin | 28.51% | 33.74% | 37.76% | 42.33% | 44.45% | 48.11% |
Operating Margin | -3.55% | -4.71% | -20.71% | 13.92% | 17.08% | 26.96% |
Profit Margin | -4.68% | -2.94% | -8.44% | 21.96% | 25.88% | 24.16% |
Free Cash Flow Margin | 1.49% | -8.61% | -77.36% | -7.87% | -38.41% | -13.36% |
EBITDA | 58.13 | 53.37 | -21.84 | 98.28 | 105.58 | 142.56 |
EBITDA Margin | 12.13% | 13.13% | -6.56% | 23.72% | 25.66% | 34.29% |
D&A For EBITDA | 75.13 | 72.5 | 47.16 | 40.6 | 35.32 | 30.49 |
EBIT | -16.99 | -19.13 | -69 | 57.68 | 70.27 | 112.08 |
EBIT Margin | -3.55% | -4.71% | -20.71% | 13.92% | 17.08% | 26.96% |
Effective Tax Rate | - | - | - | 12.61% | 11.35% | 13.02% |
Revenue as Reported | 223.92 | 406.37 | 333.13 | 414.3 | 411.46 | 415.73 |